Atrium Therapeutics earns $15 million milestone payment from Bristol Myers Squibb under cardiovascular collaboration
Reuters2026/08/13 12:24- Atrium Therapeutics earned a USD 15 million milestone payment from Bristol Myers Squibb tied to delivery of a lead cardiovascular compound.
- Payment falls under a global licensing and research collaboration covering multiple RNA-based cardiovascular programs.
- Agreement includes eligibility for up to about USD 1.35 billion in R&D milestones, up to about USD 825 million in commercial milestones.
- Bristol Myers Squibb will fund future clinical development, regulatory filings, and commercialization for programs from the collaboration.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ivy League’s space gamble: Harvard reveals $2.2 billions SpaceX position, its largest single stock holding
Harvard University Investment Management Company disclosed that it holds $2.2 billion worth of SpaceX shares, making it the largest single stock position in its $4.3 billion US equity portfolio. This holding originated from Harvard’s early investment in SpaceX through venture capital funds, and the position has significantly appreciated after SpaceX’s public listing in June this year. The University of California also disclosed a roughly $1 billion position in SpaceX during the same period. Over the past decade, endowment funds from several universities have made substantial bets on private tech assets.
Crypto prices
More
